239 related articles for article (PubMed ID: 32986175)
21. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
22. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection.
Lee S; Kim SH; Park HK; Jang KT; Hwang JA; Kim S
Radiology; 2018 Aug; 288(2):456-466. PubMed ID: 29664340
[TBL] [Abstract][Full Text] [Related]
24. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma.
Lapshyn H; Schulte T; Sondermann S; May K; Petrova E; Honselmann KC; Braun R; Zemskov S; Keck T; Wellner UF; Bausch D; Bolm L
Pancreatology; 2021 Jan; 21(1):155-162. PubMed ID: 33309623
[TBL] [Abstract][Full Text] [Related]
25. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis.
Eilaghi A; Baig S; Zhang Y; Zhang J; Karanicolas P; Gallinger S; Khalvati F; Haider MA
BMC Med Imaging; 2017 Jun; 17(1):38. PubMed ID: 28629416
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
27. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
28. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma.
Daamen LA; Dorland G; Brada LJH; Groot VP; van Oosten AF; Besselink MG; Bosscha K; Bonsing BA; Busch OR; Cirkel GA; van Dam RM; Festen S; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; Los M; de Meijer VE; Nieuwenhuijs VB; Roos D; Schreinemakers JMJ; Stommel MWJ; Verdonk RC; Verkooijen HM; Molenaar IQ; van Santvoort HC;
HPB (Oxford); 2022 Apr; 24(4):535-546. PubMed ID: 34642090
[TBL] [Abstract][Full Text] [Related]
29. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
30. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria.
Bolm L; Pisuchpen N; Qadan M; Kambadakone A; Sondermann S; Mueller K; Petruch N; May K; Zelga P; Nebbia M; Michelakos T; Baba T; Roldan J; Harrison JM; Honselmann KC; Keck T; Lillemoe KD; Ferrone CR; Wellner UF; Fernandez-Del Castillo C
Ann Surg; 2022 Aug; 276(2):215-221. PubMed ID: 36036988
[TBL] [Abstract][Full Text] [Related]
31. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
[TBL] [Abstract][Full Text] [Related]
32. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma.
Attiyeh MA; Chakraborty J; McIntyre CA; Kappagantula R; Chou Y; Askan G; Seier K; Gonen M; Basturk O; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Allen PJ; Iacobuzio-Donahue CA; Simpson AL; Do RK
Abdom Radiol (NY); 2019 Sep; 44(9):3148-3157. PubMed ID: 31243486
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens.
Ma C; Yang P; Li J; Bian Y; Wang L; Lu J
Abdom Radiol (NY); 2020 Mar; 45(3):782-788. PubMed ID: 31292672
[TBL] [Abstract][Full Text] [Related]
34. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.
Bae JS; Kim JH; Joo I; Chang W; Han JK
Eur Radiol; 2019 Jul; 29(7):3714-3724. PubMed ID: 30899975
[TBL] [Abstract][Full Text] [Related]
35. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing.
Yao J; Shi Y; Cao K; Lu L; Lu J; Song Q; Jin G; Xiao J; Hou Y; Zhang L
Med Image Anal; 2021 Oct; 73():102150. PubMed ID: 34303891
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.
Zhang LP; Ren H; Du YX; Wang CF
World J Gastroenterol; 2020 Dec; 26(46):7382-7404. PubMed ID: 33362391
[TBL] [Abstract][Full Text] [Related]
37. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma.
Kim HJ; Park MS; Lee JY; Han K; Chung YE; Choi JY; Kim MJ; Kang CM
Cancer Res Treat; 2019 Jan; 51(1):24-33. PubMed ID: 29397657
[TBL] [Abstract][Full Text] [Related]
38. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria.
Yang HK; Park MS; Choi M; Shin J; Lee SS; Jeong WK; Hwang SH; Choi SH
Abdom Radiol (NY); 2021 Nov; 46(11):5201-5217. PubMed ID: 34331549
[TBL] [Abstract][Full Text] [Related]
40. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
